ESLA Valuation

Estrella Immunopharma Inc

Add to Watchlist

Advanced Chart

1.160

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

ESLA Relative Valuation

ESLA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ESLA is overvalued; if below, it's undervalued.

Historical Valuation

Estrella Immunopharma Inc (ESLA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.35. The fair price of Estrella Immunopharma Inc (ESLA) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：1.16

Fair

-2.27

Trailing

Forward

0.00

EV/EBITDA

Estrella Immunopharma Inc. (ESLA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-1.21

EV/EBIT

Estrella Immunopharma Inc. (ESLA) has a current EV/EBIT of -1.21. The 5-year average EV/EBIT is -0.20. The thresholds are as follows: Strongly Undervalued below -1.01, Undervalued between -1.01 and -0.60, Fairly Valued between 0.21 and -0.60, Overvalued between 0.21 and 0.61, and Strongly Overvalued above 0.61. The current Forward EV/EBIT of -1.21 falls within the Strongly Undervalued range.

0.00

Estrella Immunopharma Inc. (ESLA) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-1.13

P/OCF

Estrella Immunopharma Inc. (ESLA) has a current P/OCF of -1.13. The 5-year average P/OCF is -0.20. The thresholds are as follows: Strongly Undervalued below -1.01, Undervalued between -1.01 and -0.60, Fairly Valued between 0.21 and -0.60, Overvalued between 0.21 and 0.61, and Strongly Overvalued above 0.61. The current Forward P/OCF of -1.13 falls within the Strongly Undervalued range.

0.00

P/FCF

Estrella Immunopharma Inc. (ESLA) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Estrella Immunopharma Inc (ESLA) has a current Price-to-Book (P/B) ratio of -7.05. Compared to its 3-year average P/B ratio of 31.39 , the current P/B ratio is approximately -122.47% higher. Relative to its 5-year average P/B ratio of 26.39, the current P/B ratio is about -126.73% higher. Estrella Immunopharma Inc (ESLA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -27.74%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -27.74% , the current FCF yield is about -100.00% lower.

-7.05

P/B

Median3y

31.39

Median5y

26.39

-6.28

FCF Yield

Median3y

-27.74

Median5y

-27.74

Competitors Valuation Multiple

The average P/S ratio for ESLA's competitors is 0.00, providing a benchmark for relative valuation. Estrella Immunopharma Inc Corp (ESLA) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ESLA.O

Estrella Immunopharma Inc

Century Therapeutics Inc

Jasper Therapeutics Inc

Sonnet Biotherapeutics Holdings Inc

Loss

39.05M

Performance Decomposition

Market capitalization of ESLA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ESLA in the past 1 year is driven by Unknown.